EFDID: 467555EFD: View Filing

Issuer: Aspargo Laboratories, Inc. (0001805092) - D

Accession: 0001753926-22-001525 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001805092
  • Entity Name:
    Aspargo Laboratories, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2019)
  • Address:
    550 SYLVAN AVENUE
    ENGLEWOOD CLIFFS, NJ 07632
  • Persons:
    Related Persons 3
    Michael Demurjian
    Executive Officer
    Michael Rice
    Director
    Fred Biehl
    Director
EDGAR: Offering Information
  • Accession Date:
    12/05/2022
  • First Sale Date:
    11/28/2022
  • Offering Amount:
    $15,000,000
  • Amount Sold:
    $290,000
  • Amount Remaining:
    $14,710,000
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices
View Notices

Notices found in EFD

Filed:CA, CT, MA, NC, NJ, NY
Inactive:NV, SC
EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
Axiom Capital Management, Inc. 26580 Eric Miller None CA, FL, NV, NJ, NY, SC
Newbridge Securities Corporation 104065 Gene Abrams None CA, FL, NV, NJ, NY, SC
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Aspargo Laboratories, Inc./s/ Michael DemurjianMichael DemurjianChairman & CEO2022-12-05